Significant positive changes in investment behavior have recently occurred for Dr Reddy’S Laboratories Ltd (NYSE: RDY): its shorter term price trend turned up.
Dr Reddy’S Laboratories Ltd (NYSE: RDY). Meaningful positive changes in fundamentals have recently occurred: the consensus estimate for March, 2024 increased significantly, the consensus estimate for March, 2023 increased significantly, and significant quarterly earnings acceleration occurred.
In light of these very positive signals we are reviewing our current Overall Rating of C. We would view the shares with optimism pending completion of this review in the next several days.
Current PriceTarget Research Rating
RDY is expected to continue to be a major Value Builder reflecting capital returns that are forecasted to exceed the cost of capital.
Dr Reddy’S Laboratories has a current Value Trend Rating of C (Neutral). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Dr Reddy’S Laboratories has a poor Appreciation Score of 26 but a very high Power Rating of 87, leading to the Neutral Value Trend Rating.
Recent Price Action
On 12/1/23, Dr Reddy’S Laboratories Ltd (NYSE: RDY) stock declined slightly by -0.5%, closing at $69.58. Moreover, trading volume in this decline was above average at 123% of normal. Relative to the market the stock has been exceptionally strong over the last nine months and has risen 2.8% during the last week.
Be the first to comment